Watch for New Rx PO Semaglutide During Transitions of Care

February 2026

You’ll see patients admitted on Rx semaglutide tablets (Wegovy), the first ORAL GLP-1 agonist FDA-approved for obesity and overweight.

New oral semaglutide is the same med as injectable Wegovy for weight loss...or injectable Ozempic or oral Rybelsus for type 2 diabetes.

But it’s taken DAILY...versus weekly like the injection.

Practical advice for a better career, with unlimited access to CE

Hospital Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Medication Errors Spot and Stop Common Errors With GLP-1 Agonists
Allergic Reactions Dig Deeper When Patients Report Antibiotic Allergies
Med Safety Help Leave Room for Safety When Boarding Patients in the ED
Parenteral Nutrition Focus on Safety Limits With Peripheral Parenteral Nutrition
COPD Be Prepared to Dispense More Combo Meds for COPD
Calculations Count On These Tips for Pharmacy Calculations
Immunizations Listen for Questions About Childhood Immunizations
Obesity & Weight Loss Watch for New Rx PO Semaglutide During Transitions of Care